Journal of Isfahan Medical School

Journal of Isfahan Medical School

The Prescription Rate of SGLT Inhibitors and GLP1 Receptor Agonists in Patients with Type 2 DM, According to the ADA and ESC Criteria in Three Diabetes Centers in Iran

Document Type : Original Article (s)

Authors
Raheleh Sadat Sajad 1
Mahbube Baghban 2
Mansour Siavash 3
Hassan Rezvanian 4
Mojtaba Akbari 4
Mojgan Golbidi 4
Roya Adelnia 4
Tahereh Sadeghi 4
1 Assistant Professor of Endocrinology, Isfahan Endocrine and Metabolism Research Center, Isfahan, Iran
2 Resident of Endocrinology, Isfahan Endocrine and Metabolism Research Center, Isfahan, Iran
3 Professor of Endocrinology, Isfahan Endocrine and Metabolism Research Center, Isfahan, Iran
4 Isfahan Endocrine & Metabolism Research center, Isfahan University of Medical Sciences, Isfahan, Iran
10.48305/jims.v43.i809.0302
Abstract
Background: This study aimed to determine the prescription rates of SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) in type 2 diabetes (T2D) patients according to European Society of Cardiology (ESC) and American Diabetes Association (ADA) guidelines at three Iranian diabetes centers.
Methods: A cross-sectional analysis was conducted on the medical records of T2D patients (n = 303) from three centers: the Isfahan Endocrine Research Center (n = 129), the Isfahan Social Security Clinic (n = 30), and the Qom Social Security Clinic (n = 144), between 2019 and 2021.
Findings: According to ESC and ADA criteria, 84% and 68% of patients were eligible for SGLT2i and GLP-1 RA, respectively. However, only 13.5% received these medications. Key reasons for non-prescription included: high cost, insurance non-coverage due to concurrent insulin pen use (28 patients), injection aversion, and physicians’ unfamiliarity with these drug classes.
Conclusion: The overall utilization of SGLT2i and GLP-1 RA among eligible patients remains low. Our findings highlight opportunities to optimize the use of these drugs for preventing future cardiovascular complications, such as periodic training for primary care physicians and expanding insurance coverage to ensure equitable access.

Highlights

Raheleh Sadat Sajad: Google Scholar, PubMed

Mahbube Baghban: Google Scholar, PubMed

Mansour Siavash:  Google Scholar, PubMed

Keywords
American Diabetes Association (ADA)
Diabetes Mellitus
Type 2
European Society of Cardiology (ESC)
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA)
Sodium-Glucose Transporter 2 Inhibitors (SGLT2i)
Subjects
  1. Mishra V, Nayak P, Sharma M, Albutti A, Alwashmi AS, Aljasir MA, et al. Emerging Treatment Strategies for Diabetes Mellitus and Associated Complications: An Update. Pharmaceutics 2021; 13(10): 1568.
  2. Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010; 122: 844-6.
  3. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 2017; 60(2): 215-25.
  4. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab 2015; 6: 19-28.
  5. Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab 2024; 15: 20420188231222367.
  6. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Clinical assessment of cardiovascular damage [online 2019]. Available from: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/2019-guidelines-on-diabetes-pre-diabetes.
  7. American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021; 44(Suppl 1): S111-S124.
  8. Korayem GB, Alshaya OA, Alghamdi AA, Alanazi SS, Almutib RT, Alsaileek M, et al. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study. Front Public Health 2022; 10: 1031306.
  9. Pantalone KM, Misra-Hebert A, Hobbs TM, Ji X, Kong SX, Milinovich A, et al. Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. Cardiovasc Diabetol 2018; 17(1): 54.
  10. Gao Y, Peterson E, Pagidipat N. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits. Am Heart J 2022; 224: 47-53.
  11. Khunti K, Jabbour S, Cos X, Mudaliar S, Mende C, Bonaca M, et al. Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice. Diabetes Obes Metab 2022; 24(7): 1187-96.
  12. Mody R, Manjelievskaia J, Marchlewicz EH, Malik RE, Zimmerman NM, Irwin DE, Yu M. Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up. Clin Ther 2022; 44(4): 537-554.
  13. Eberly LA, Yang L, Essien UR, Eneanya ND, Julien HM, Luo J, et al. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients with Diabetes in the US. Health Forum  JAMA 2021; 2(12): e214182.
Journal of Isfahan Medical School
Volume 43, Issue 809
1st Week, June
May and June 2025
Pages 302-309

  • Receive Date 24 January 2025
  • Accept Date 01 June 2025